Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Conclusion. Severe gastrointestinal toxicities are uncommon with BRAF and MEK inhibitors, although cases of colitis and intestinal perforation have already been reported in literature. The pathogenesis seems to be related to the MAPK pathway inhibition performed by MEK inhibitors. These adverse events should be accounted given the potential to evolve into life-threatening conditions.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Colonoscopy | CT Scan | Drugs & Pharmacology | Gastroenterology | Hypertension | Investigational New Drugs | Liver | Lung Cancer | Non-Small Cell Lung Cancer | PET Scan | Toxicology | Urology & Nephrology